Unknown

Dataset Information

0

Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib.


ABSTRACT: Medulloblastoma is an aggressive primitive neuroectodermal tumor of the cerebellum that is rare in adults. Medulloblastomas fall into 4 prognostically significant molecular subgroups that are best defined by experimental gene expression profiles: the WNT pathway, sonic hedgehog (SHH) pathway, and subgroups 3 and 4 (non-SHH/WNT). Medulloblastoma of adults belong primarily to the SHH category. Vismodegib, an SHH-pathway inhibitor FDA-approved in 2012 for treatment of basal cell carcinoma, has been used successfully in the setting of chemorefractory medulloblastoma, but not as a first-line therapy. In this report, we describe a sustained response of an unresectable multifocal form of adult medulloblastoma to vismodegib. Molecular analysis in this case revealed mutations in TP53 and a cytogenetic abnormality, i17q, that is prevalent and most often associated with subgroup 4 rather than the SHH-activated form of medulloblastoma. Our findings indicate that vismodegib may also block alternate, non-canonical forms of downstream SHH pathway activation. These findings provide strong impetus for further investigation of vismodegib in clinical trials in the first-line setting for pediatric and adult forms of medulloblastoma.

SUBMITTER: Lou E 

PROVIDER: S-EPMC5079386 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib.

Lou Emil E   Schomaker Matthew M   Wilson Jon D JD   Ahrens Mary M   Dolan Michelle M   Nelson Andrew C AC  

Cancer biology & therapy 20160929 10


Medulloblastoma is an aggressive primitive neuroectodermal tumor of the cerebellum that is rare in adults. Medulloblastomas fall into 4 prognostically significant molecular subgroups that are best defined by experimental gene expression profiles: the WNT pathway, sonic hedgehog (SHH) pathway, and subgroups 3 and 4 (non-SHH/WNT). Medulloblastoma of adults belong primarily to the SHH category. Vismodegib, an SHH-pathway inhibitor FDA-approved in 2012 for treatment of basal cell carcinoma, has been  ...[more]

Similar Datasets

| S-EPMC5839382 | biostudies-literature
2016-03-14 | E-GEOD-77042 | biostudies-arrayexpress
| S-EPMC4096181 | biostudies-literature
| S-EPMC7430762 | biostudies-literature
| S-EPMC5775338 | biostudies-literature
| S-EPMC3800039 | biostudies-literature
| S-EPMC8563312 | biostudies-literature
2020-04-23 | PXD016832 | Pride
2016-03-14 | GSE77042 | GEO
| S-EPMC8001973 | biostudies-literature